Patients with chemorefractory metastatic colorectal cancer derive no overall survival benefit from giving anti-EGFR ...

TME Pharma N.V. (($DE:0N6A)) announced an update on their ongoing clinical study. The clinical study titled An Open-label Phase 2 Study of ...

Patients with advanced triple negative breast cancer ineligible for immunotherapy may overcome their typically poor prognosis with antibody-drug conjugates, suggest two trials presented at ESMO 2025.

Patients with previously untreated, locally advanced, unresectable or metastatic triple-negative breast cancer who are not ...

ADC usage in breast cancer treatment increased 3.7-fold from 2021 to 2023, with significant reductions in median time to ...

For patients with advanced or metastatic RCC, fruquintinib plus sintilimab improves PFS compared to investigator’s choice of axilitinib or everolimus.

BERLIN -- The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) significantly ...

The FDA has granted breakthrough therapy designation to zenocutuzumab (Bizengri) for the treatment of patients with advanced ...

Metastatic cancer, the form of cancer that spreads from its original site to distant parts of the body, often provides warning signs long before diagnosis. These signals, frequently dismissed as ...

Sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival compared to chemotherapy in HR-positive, ...

BERLIN -- Administering bone-modifying agents (BMAs) every 24 weeks after long-term use was a safe and effective strategy for ...